Tradestie Institutional Equity Comparison Engine

VERA vs ZBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while VERA counters with relative strength in Growth & Margin. Fundamentally, VERA trades at N/M Forward P/E with -4160.1% operating margin (+0.0% YoY revenue) versus ZBIO at N/M Forward P/E and -2747.5% operating margin (-100.0% YoY). In options structure, VERA sits in BREAKDOWN (68th %ile IV; Dealer Gamma Walls on Pro) against ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
VERA N/M vs ZBIO N/M Fwd P/E
Growth & Margin Winner VERA
Op Margin -4160.1% vs -2747.5% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner ZBIO
1Y -4.9% vs -21.7% ยท 52W Pos 2% vs 46%
Options & Structure Winner ZBIO
BREAKDOWN (68th %ile IV) vs CONSOLIDATION (13th %ile IV)
VERA NASDAQ
Vera Therapeutics, Inc. Class A Common Stock
Pharmaceutical Preparations
$26.97
-4.02% 1D
Market Cap $2.0B
1M Return -3.26%
1Y Return -4.93%
Forward P/E N/M
Unified AI Score
45.9 / 100 HOLD
Tech 32.0 Fund 51.0 Flow 69.0 Mom 60.0
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: VERA -4.93% ZBIO -21.68% Spread: +16.75 pp (VERA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
VERA TTM Op. Margin: -4160.1% ZBIO TTM Op. Margin: -2747.5%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VERA vs ZBIO. Trailing 12-month operating profitability (VERA -4160.1% vs ZBIO -2747.5%) and valuation multiples (VERA N/M vs ZBIO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: VERA (4) vs ZBIO (3)
Institutional Metric VERA ZBIO Criterion Row Winner
Market Capitalization Scale $2.0B $1.9B Larger Scale VERA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -100.0% Higher Growth VERA
Operating Margin (TTM) Profitability -4160.1% -2747.5% Higher Margin ZBIO
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -113.5% -265.1% Higher ROE VERA
52-Week Range Position Momentum 2% ($26โ€“$56) 46% ($14โ€“$45) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.11ฮฒ ยท 57% Vol 1.16ฮฒ ยท 59% Vol Lower Realized Risk VERA
Unified Institutional Score Composite Signal 45.9 / 100 (HOLD) 49.4 / 100 (HOLD) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full VERA vs ZBIO Buy Guide
VERA BREAKDOWN
98d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 68th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live VERA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither VERA nor ZBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.